OncoTherapy Science, Inc.
Total Valuation
JPYAs of March 31, 2026, OncoTherapy Science, Inc. carries a market capitalization of 8.06B, placing it among publicly traded companies globally. Its enterprise value stands at 5.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.06B |
| Enterprise Value | 5.97B |
Important Dates
OncoTherapy Science, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.
| Earnings Date | 11/9/2026 |
Share Statistics
As of March 31, 2026, OncoTherapy Science, Inc. has 383.64M shares outstanding.
| Shares Outstanding | 383.64M |
Valuation Ratios
These figures are as of March 31, 2026.
| PB Ratio | 3.76 |
| P/TBV Ratio | 3.76 |
Financial Position
As of March 31, 2026, OncoTherapy Science, Inc. maintains a current ratio of 13.59, meaning it holds 13.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.59 |
| Quick Ratio | 12.29 |
Financial Efficiency
These figures cover the twelve months ended March 31, 2026.
| Employee Count | 46.75 |
Stock Price Statistics
JPYAs of the close on October 22, 2026, OncoTherapy Science, Inc.'s stock has declined approximately 25.00% over the past 52 weeks. The 50-day moving average sits at 20.66, while the 200-day moving average is 21.13.
| 52-Week Price Change | -25.00% |
| 50-Day Moving Average | 20.66 |
| 200-Day Moving Average | 21.13 |
Balance Sheet
JPYThese figures are as of March 31, 2026. Total book value stands at 2.14B, with working capital of 2.14B providing operational flexibility.
| Cash & Cash Equivalents | 2.09B |
| Net Debt | -2.09B |
| Equity (Book Value) | 2.14B |
| Book Value Per Share | 5.58 |
| Working Capital | 2.14B |
Stock Splits
OncoTherapy Science, Inc.'s most recent stock split took place on September 26, 2013 with a 1:500 split ratio.
| Last Split Date | 9/26/2013 |
| Split Ratio | 1:500 |